{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:05:28Z","timestamp":1767337528814},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,6,12]],"date-time":"2015-06-12T00:00:00Z","timestamp":1434067200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s00280-015-2783-y","type":"journal-article","created":{"date-parts":[[2015,6,12]],"date-time":"2015-06-12T00:52:05Z","timestamp":1434070325000},"page":"317-323","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A phase II study of sorafenib, oxaliplatin, and 2\u00a0days of high-dose capecitabine in advanced pancreas cancer"],"prefix":"10.1007","volume":"76","author":[{"given":"Rory J.","family":"Makielski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam J.","family":"Lubner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel L.","family":"Mulkerin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne M.","family":"Traynor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Groteluschen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Eickhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noelle K.","family":"LoConte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,6,12]]},"reference":[{"key":"2783_CR1","author":"RL Siegel","year":"2015","unstructured":"Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin. doi: 10.3322\/caac.21254","journal-title":"CA Cancer J Clin"},{"key":"2783_CR2","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Hoff Von","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691\u20131703. doi: 10.1056\/NEJMoa1304369","journal-title":"N Engl J Med"},{"key":"2783_CR3","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817\u20131825. doi: 10.1056\/NEJMoa1011923","journal-title":"N Engl J Med"},{"key":"2783_CR4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/sj.bjc.6600467","volume":"87","author":"SL Cheeseman","year":"2002","unstructured":"Cheeseman SL, Joel SP, Chester JD et al (2002) A \u201cmodified de Gramont\u201d regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 87:393\u2013399. doi: 10.1038\/sj.bjc.6600467","journal-title":"Br J Cancer"},{"key":"2783_CR5","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1093\/annonc\/dkf281","volume":"13","author":"W Scheithauer","year":"2002","unstructured":"Scheithauer W, Kornek GV, Raderer M et al (2002) Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I\/II study in first-line treatment of patients with advanced colorectal cancer. Ann Oncol 13:1583\u20131589","journal-title":"Ann Oncol"},{"key":"2783_CR6","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/sj.bjc.6601676","volume":"90","author":"E Cutsem Van","year":"2004","unstructured":"Van Cutsem E, Hoff PM, Harper P et al (2004) Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 90:1190\u20131197. doi: 10.1038\/sj.bjc.6601676","journal-title":"Br J Cancer"},{"key":"2783_CR7","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10637-008-9210-8","volume":"27","author":"D Mulkerin","year":"2009","unstructured":"Mulkerin D, LoConte NK, Holen KD et al (2009) A phase I study of an oral simulated FOLFOX with high dose capecitabine. Invest New Drugs 27:461\u2013468. doi: 10.1007\/s10637-008-9210-8","journal-title":"Invest New Drugs"},{"key":"2783_CR8","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","volume":"7","author":"SM Wilhelm","year":"2008","unstructured":"Wilhelm SM, Adnane L, Newell P et al (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7:3129\u20133140. doi: 10.1158\/1535-7163.MCT-08-0013","journal-title":"Mol Cancer Ther"},{"key":"2783_CR9","first-page":"545","volume":"143","author":"RH Hruban","year":"1993","unstructured":"Hruban RH, van Mansfeld AD, Offerhaus GJ et al (1993) K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 143:545\u2013554","journal-title":"Am J Pathol"},{"key":"2783_CR10","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099\u20137109. doi: 10.1158\/0008-5472.CAN-04-1443","journal-title":"Cancer Res"},{"key":"2783_CR11","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/jcp.21753","volume":"220","author":"P Ulivi","year":"2009","unstructured":"Ulivi P, Arienti C, Amadori D et al (2009) Role of RAF\/MEK\/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. J Cell Physiol 220:214\u2013221. doi: 10.1002\/jcp.21753","journal-title":"J Cell Physiol"},{"key":"2783_CR12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125\u2013134. doi: 10.1056\/NEJMoa060655","journal-title":"N Engl J Med"},{"key":"2783_CR13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3816\/CCC.2010.n.021","volume":"9","author":"SJ Lubner","year":"2010","unstructured":"Lubner SJ, Loconte NK, Holen KD et al (2010) A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer. Clin Colorectal Cancer 9:157\u2013161. doi: 10.3816\/CCC.2010.n.021","journal-title":"Clin Colorectal Cancer"},{"key":"2783_CR14","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s10637-012-9916-5","volume":"31","author":"NK LoConte","year":"2013","unstructured":"LoConte NK, Holen KD, Schelman WR et al (2013) A phase I study of sorafenib, oxaliplatin and 2\u00a0days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. Invest New Drugs 31:943\u2013948. doi: 10.1007\/s10637-012-9916-5","journal-title":"Invest New Drugs"},{"key":"2783_CR15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. doi: 10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"2783_CR16","unstructured":"CTEP (2006) Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf . Accessed 9 June 2015"},{"key":"2783_CR17","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/annonc\/mdt166","volume":"24","author":"OE Rahma","year":"2013","unstructured":"Rahma OE, Duffy A, Liewehr DJ et al (2013) Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol 24:1972\u20131979. doi: 10.1093\/annonc\/mdt166","journal-title":"Ann Oncol"},{"key":"2783_CR18","first-page":"2635","volume":"59","author":"V Berk","year":"2012","unstructured":"Berk V, Ozdemir N, Ozkan M et al (2012) XELOX vs. FOLFOX4 as second line chemotherapy in advanced pancreatic cancer. Hepatogastroenterology 59:2635\u20132639. doi: 10.5754\/hge12181","journal-title":"Hepatogastroenterology"},{"key":"2783_CR19","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1200\/JCO.2013.49.4757","volume":"32","author":"TH Cartwright","year":"2014","unstructured":"Cartwright TH (2014) Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine-based therapy. J Clin Oncol\u00a032:5s (suppl; abstr 4132)","journal-title":"J Clin Oncol"},{"key":"2783_CR20","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/1471-2407-14-441","volume":"14","author":"A Zaanan","year":"2014","unstructured":"Zaanan A, Trouilloud I, Markoutsaki T et al (2014) FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study. BMC Cancer 14:441. doi: 10.1186\/1471-2407-14-441","journal-title":"BMC Cancer"},{"key":"2783_CR21","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/sj.bjc.6605374","volume":"101","author":"C Yoo","year":"2009","unstructured":"Yoo C, Hwang JY, Kim J-E et al (2009) A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 101:1658\u20131663. doi: 10.1038\/sj.bjc.6605374","journal-title":"Br J Cancer"},{"key":"2783_CR22","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1200\/JCO.2011.36.7771","volume":"30","author":"J Baselga","year":"2012","unstructured":"Baselga J, Segalla JGM, Roch\u00e9 H et al (2012) Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol 30:1484\u20131491. doi: 10.1200\/JCO.2011.36.7771","journal-title":"J Clin Oncol"},{"key":"2783_CR23","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1158\/1078-0432.CCR-13-0107","volume":"19","author":"J Tabernero","year":"2013","unstructured":"Tabernero J, Garcia-Carbonero R, Cassidy J et al (2013) Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. Clin Cancer Res 19:2541\u20132550. doi: 10.1158\/1078-0432.CCR-13-0107","journal-title":"Clin Cancer Res"},{"key":"2783_CR24","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1200\/JCO.1998.16.11.3537","volume":"16","author":"E L\u00e9vy","year":"1998","unstructured":"L\u00e9vy E, Piedbois P, Buyse M et al (1998) Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 16:3537\u20133541","journal-title":"J Clin Oncol"},{"key":"2783_CR25","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/annonc\/mds135","volume":"23","author":"A Gon\u00e7alves","year":"2012","unstructured":"Gon\u00e7alves A, Gilabert M, Fran\u00e7ois E et al (2012) BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol 23:2799\u20132805. doi: 10.1093\/annonc\/mds135","journal-title":"Ann Oncol"},{"key":"2783_CR26","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.dld.2013.09.020","volume":"46","author":"S Cascinu","year":"2014","unstructured":"Cascinu S, Berardi R, Sobrero A et al (2014) Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: a GISCAD randomized phase II study. Dig Liver Dis 46:182\u2013186. doi: 10.1016\/j.dld.2013.09.020","journal-title":"Dig Liver Dis"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2783-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-015-2783-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2783-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T19:06:13Z","timestamp":1566846373000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-015-2783-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,12]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["2783"],"URL":"https:\/\/doi.org\/10.1007\/s00280-015-2783-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,12]]}}}